| [1] | LI Bin, TAO Zhonghua, HU Xichun. 
														
															Precision diagnosis and treatment of breast cancer in the post-CDK4/6 inhibitor era
														[J]. China Oncology, 2025, 35(3): 273-282. | 
																																																																																
													| [2] | ZHAO Kaile, WANG Lei, GENG Jianxiong, CUI Chengwei, YU Yan. 
														
															Research status and prospects of treatment for malignant pleural mesothelioma
														[J]. China Oncology, 2025, 35(3): 326-332. | 
																																																																																
													| [3] | LIN Jialin, WANG Wenna, XU Binghe. 
														
															Current status and future perspectives of antibody-drug conjugates in breast cancer therapy
														[J]. China Oncology, 2025, 35(2): 154-166. | 
																																																																																
													| [4] | LU Yongjin, SHI Zhiqiang, LI Tong, WANG Yongsheng, QIU Pengfei. 
														
															Retrospective study on regional lymph node radiotherapy after axillary dissection exemption in breast cancer patients with sentinel lymph node positive status
														[J]. China Oncology, 2025, 35(2): 228-236. | 
																																																																																
													| [5] | GENG Qianqian, YANG Aimin. 
														
															Progress and prospect on treatment for radioiodine-refractory thyroid cancer
														[J]. China Oncology, 2025, 35(1): 30-39. | 
																																																																																
													| [6] | LI Ruping, YANG Hui. 
														
															Current status and future prospects of clinical trials for radioiodine-refractory thyroid cancer
														[J]. China Oncology, 2025, 35(1): 40-48. | 
																																																																																
													| [7] | LIN Qiuyu, WANG Yuxin, LIN Chenghe. 
														
															Application and prospect of targeted therapy and immunotherapy in radioiodine-refractory differentiated thyroid cancer
														[J]. China Oncology, 2025, 35(1): 58-67. | 
																																																																																
													| [8] | FENG Xinying, WANG Bing, LIU Peifeng. 
														
															Innovations and challenges in intraperitoneal chemotherapy for peritoneal metastatic carcinoma
														[J]. China Oncology, 2024, 34(9): 827-837. | 
																																																																																
													| [9] | CAO Xiaoshan, YANG Beibei, CONG Binbin, LIU Hong. 
														
															The progress of treatment for brain metastases of triple-negative breast cancer
														[J]. China Oncology, 2024, 34(8): 777-784. | 
																																																																																
													| [10] | HUANG Sijie, KANG Xun, LI Wenbin. 
														
															Clinical research progress of intrathecal therapy in the treatment of leptomeningeal metastasis
														[J]. China Oncology, 2024, 34(7): 695-701. | 
																																																																																
													| [11] | LIN Yicong, WANG Yue, XUE Qianqian, ZHENG Qiang, JIN Yan, HUANG Ziling, LI Yuan. 
														
															Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications
														[J]. China Oncology, 2024, 34(4): 368-379. | 
																																																																																
													| [12] | XU Yonghu, XU Dazhi. 
														
															Progress and prospects of gastric cancer treatment in the 21st century
														[J]. China Oncology, 2024, 34(3): 239-249. | 
																																																																																
													| [13] | CHEN Yifan, LI Ting, WANG Biyun. 
														
															Research progress of CCR8 in tumor immunotherapy
														[J]. China Oncology, 2024, 34(3): 299-305. | 
																																																																																
													| [14] | HU Xiaoyu, CAI Yuwen, YE Fugui, SHAO Zhimin, HU Weigang, YU Keda. 
														
															Impact of BRCA1/2 germline mutation on the incidence of second primary cancer following postoperative radiotherapy in patients with triple-negative breast cancer
														[J]. China Oncology, 2024, 34(2): 185-190. | 
																																																																																
													| [15] | LIU Zhiyu, XU Dong, CHEN Xihao, LI Jipeng. 
														
															Influencing factors and establishment of a prediction model for the tumor regression after neoadjuvant chemoradiotherapy in locally advanced rectal cancer
														[J]. China Oncology, 2024, 34(2): 191-200. |